Clinical Trial

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

Name: Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer — clinical trial record (NCT07645651)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-08.

Trial Details

NCT Number	NCT07645651
Lead Sponsor	University of Washington Collaborators: Lopker Family Foundation, Carrick Therapeutics Limited, The V Foundation for Cancer Research
Conditions	Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Enrollment	15 participants
Start Date	2026-10-01
Primary Completion	2027-07-14 (estimated)
Study Completion	2027-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-31